Tauriga Sciences Inc. Appoints 20 Year Pharmaceutical Industry Veteran to its Board of Advisors
NEW YORK, NY / ACCESSWIRE / April 6, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or “the Company”), a diversified life sciences technology Company, today announced that it has appointed Mr. Frank P. Orlowski to its Advisory Board effective immediately. Mr. Orlowski is a seasoned pharmaceutical industry executive, with more than 20 years’ experience at one of the industry’s largest global firms.
His main role with Tauriga will be assisting the Board of Directors in its efforts to evaluate potential acquisition targets in the life sciences space.
The Company is currently in the process of considering several potential opportunities and is pleased to work with Mr. Orlowski throughout the critical due diligence process.
Please see below, Personal BIO — Frank P. Orlowski, age 44
Mr. Frank P. Orlowski serves as Senior Director Finance, emerging markets and transition manufacturing sites at a Global Pharmaceutical Company (“the Pharma Company”). Mr. Orlowski is responsible for managing all aspects of Emerging Markets Manufacturing Supply Finance. In this global role he develops operational strategies for internal and external pharmaceutical supply chain and sourcing throughout Asia, Africa/Middle East and South America. As a global leader he is highly effective working in a multi-cultural, global organization partnering with senior government officials and business leaders, both inside and outside the Pharma Company and the pharmaceutical industry. He manages a large team across the globe and is responsible for a yearly operating budget of over $900 million. The specific countries which he supports from a manufacturing and business development standpoint include Argentina, Brazil, China (all provinces), Egypt, India, Indonesia, Japan, Korea, Mexico, Morocco, Russia, Singapore, Turkey, Tunisia, Thailand and Venezuela. He has over 20 years’ experience in the pharmaceutical industry in positions of increased responsibility in strategy, finance and operations. Prior to his work in the pharmaceutical industry, he worked at Accenture on various successful strategic consulting engagements in manufacturing. He was responsible for the global integration of several major acquisitions. He was Project Lead for the global rollout of several widely used information systems. He sits on the leadership team of several innovating manufacturing and drug development teams within the Pharma Company alongside senior Company scientists. He sits on the leadership team of several innovating manufacturing and drug development teams within the Pharma Company alongside senior Company scientists. This includes evaluating external business development and licensing opportunities. In 2015, Mr. Orlowski was appointed to the Board of the American Cancer Society and serves on the Executive Board of the National Corporate Theatre Forward. He completed two New York City Marathons and over 20 half marathons. Mr. Orlowski earned a BS in accounting from Providence College and an MBA from NYU Stern School of Business.
About TAURIGA SCIENCES, INC.:
Tauriga Sciences, Inc. (OTC PINK: TAUG) is a diversified life sciences company focused on generating profitable revenues through its present and future holdings. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
This release contains the Company’s forward-looking statements which are based on management’s current expectations and assumptions as of April 5, 2016, regarding the Company’s business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.
Tauriga Sciences, Inc.
Mr. Seth Shaw
SOURCE: Tauriga Sciences, Inc.